Latest Industry Updates
From company milestones to industry breakthroughs, uncover the stories making waves and shaping the narrative in real time.
- Press Release
King of Prussia, PA – May 3, 2023: CluePoints, the premier provider of Risk-Based Study Execution...
- Press Release
King of Prussia, PA: RBQM leader, CluePoints, has today announced that Amit Patel will join as...
- Featured Article
Using key risk indicators (KRIs) can improve clinical trial data quality in 80% of the sites...
Source: Applied Clinical Trials
- Featured Article
Since the release of ICH E6(R2), multiple efforts have been made to interpret the requirements and...
- Read
Source: Springer Link
- Press Release
King of Prussia, PA – March 23rd, 2023: CluePoints, the premier provider of Risk-Based Study Execution...
- Featured Article
An expectation for the use of quality tolerance limits (QTLs) was formally established in the International...
Source: Applied Clinical Trials
- Featured Article
Clinical research is evolving rapidly, with the digitalization of trials creating a new modus operandi and...
Source: Applied Clinical Trials
- Press Release
Authors: Steve Young, Chief Scientific Officer Sylviane de Viron, Data and Knowledge Manager In the face...
- Press Release
King of Prussia, PA – 6 February 2023: CluePoints, the premier provider of Risk-Based Study Execution...
- Press Release
King of Prussia, PA – December 13, 2022: RBQM leader, CluePoints, has today announced Andy Cooper...
- Featured Article
Risk-based approaches to monitoring clinical trials were brought to the forefront with an FDA guidance published...
Source: Applied Clinical Trials
- Featured Article
Key risk indicators (KRIs) are metrics designed to identify risks of specific interest to study teams...
Source: Applied Clinical Trials
- Press Release
On July 28, CluePoints is teaming up with DIA for a webinar to explore how the...
- Press Release
Personalizing the Power of Statistical Analysis and Data Visualization King of Prussia, PA: CluePoints, the premier...
- Press Release
RISK MANAGEMENT SOLUTION ADDRESSES FDA, EMA, PMDA & MHRA CORONAVIRUS ADVICE King of Prussia, PA: CluePoints,...
- Press Release
King of Prussia, PA: CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality...
- Press Release
Risk Planning Guidance Addresses FDA, EMA, PMDA and MHRA Coronavirus Advice King of Prussia, PA: CluePoints,...
- Press Release
We’re delighted to announce that the recording for our COVID-19 webinar has been posted! About the...
- Press Release
Remote monitoring is mitigating the impact of SARS-CoV-2 on clinical trials, marking an acceleration in the...
- Press Release
King of Prussia, PA: CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality...
- Press Release
KING OF PRUSSIA, PA: CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality...
- Press Release
KING OF PRUSSIA, PA– FDA and its stakeholders have an interest in assuring the integrity of...
- Press Release
“I KNOW ICH E6 (R2) COMPLIANCE INSISTS ON A RISK-BASED APPROACH TO RUNNING MY TRIALS, BUT...
- Press Release
Strategic collaboration leverages CluePoints’ Central Statistical Monitoring (CSM) technology to enhance data quality and reduce operational...
- Featured Article
Artificial Intelligence (AI) continues to gain momentum in the pharmaceutical sector, but can it truly deliver...
Source: Health Tech World
- Featured Article
Dr Laura Trotta gives us an insight into her role at CluePoints and shares some of...
Source: Health Tech World
- Featured Article
Sas Maheswaran discusses how artificial intelligence, data and strategic partnerships can make clinical trials more sustainable...
Source: ONdrugDelivery
- Featured Article
Andrew Cooper, CEO, CluePoints, explores how AI is transforming clinical trials, the power of a purpose-driven...
Source: European Medical Journal GOLD
- Featured Article
The monitoring of key risk indicators (KRIs) is an established form of risk control in the...
Source: Applied Clinical Trials
- Featured Article
Richard Young, Chief Strategy Officer at CluePoints, shares insights on AI and risk-based quality management (RBQM)...
Source: The Clinical Trial Vanguard
- Featured Article
The pharmaceutical industry is poised for a transformative evolution by 2025, driven by the possibilities of...
Source: PM360
- Featured Article
Central monitoring is highly effective in detecting emerging quality issues in clinical trials, but debate continues...
Source: Applied Clinical Trials
- Featured Article
An essential component of risk-based quality management (RBQM), as detailed in both the ICH E8 (R1)...
Source: Applied Clinical Trials
- Featured Article
The need to boost education, shift culture, and embrace new technologies.
...Source: Applied Clinical Trials
- Featured Article
As an industry, we regularly discuss the benefits of adopting risk-based quality management (RBQM). The good...
Source: International Clinical Trials/European Pharmaceutical Contractors
- Featured Article
François Torche dispels the myth that, at least in RBQM, there is such a thing as...
Source: PM360
